Day: August 27, 2025
On 11 July 2025, Bigbank AS announced via a stock exchange notice the conclusion of intra-group merger agreement between Balti Võlgade Sissenõudmise Keskus OÜ (the company being acquired), a subsidiary of Bigbank AS, and OÜ Rüütli Property (the acquiring company), a subsidiary of OÜ Rüütli Majad which is a subsidiary of Bigbank AS.
Bigbank AS hereby announces that the merger was officially recorded in the Estonian commercial register on 26 August 2025. As a result, Balti Võlgade Sissenõudmise Keskus OÜ has been deleted from the commercial register as of 26 August 2025.
Bigbank AS (www.bigbank.eu), with over 30 years of operating history, is a commercial bank owned by Estonian capital. As of 31 July 2025, the bank’s total assets amounted to 3.1 billion euros, with equity of 284 million euros. Operating in nine countries, the bank...
Immuron partners with InvestorHub
Written by Customer Service on . Posted in Public Companies.
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors.
In line with the Company’s commitments to better inform and engage with investors and stakeholders, we have launched our interactive investor hub – bringing content and communication into a single integrated platform. The Company will also be regularly uploading new content via the hub, including videos accompanying select announcements, educational material, interviews and corporate research.
Chief Executive Officer, Steven Lydeamore, commented: “With a number of near term milestones coming up, there has...
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2025 interim financial results and provided corporate updates.
FINANCIAL HIGHLIGHTSAs of June 30, 2025, the total revenue of Junshi Biosciences was approximately RMB1,168 million for the first half of 2025, representing an increase of approximately 49% compared to 2024, driven mainly by pharmaceutical sales. In particular, the domestic sales revenue of our core product, TUOYI® (toripalimab), reached approximately RMB954 million, an increase of approximately 42% from 2024.
Total research and development (“R&D”) expenses of the company were approximately...
